GSK0660 is a potent and selective antagonist of PPARβ and PPARδ with IC50 values of both 155 nM, it has little or no activity on PPARα and PPARγ with IC50 values of >10 μM.

Indeglitazar (formerly PPM-204 and PLX-204) is a novel, potent and orally bioavailable peroxisome proliferator-activated receptor (PPAR) pan-agonist for all three PPAR subtypes alpha (α), delta (δ) and gamma (γ).

Choline fenofibrate (formerly also known as ABT-335 or choline salt of fenofibric acid) is a novel, synthetic phenoxy-isobutyric acid derivate with antihyperlipidemic activity that acts as an PPARα agonist.

Aleglitazar (RG-1439; RO-0728804; RG1439; RO0728804) is a novel and potent agonist of peroxisome proliferator-activated receptor (PPARα and PPARγ) with potential antidiabetic effects.

Tesaglitazar (also known as AZ-242; Galida; AR-H-039242XX) is a dual peroxisome proliferator-activated receptor (PPAR) agonist with anti-diabetic effects.

Muraglitazar (BMS-298585; BMS298585) is a novel, potent and selective Peroxime Proliferator Activated (PPAR) α/γ dual agonist with glucose- and lipid-lowering activities.

GW1929 is a novel, potent and selective PPAR-γ agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively.

GW 501516 (also known as endurobol; GW-501516; GSK-516) is a novel and potent PPARδ agonist with an EC50 of 1.1 nM.

Arhalofenate (formerly known as JNJ-39659100 and/or MBX102) is a novel, selective, partial agonist of PPAR-γ (peroxisome proliferator-activated receptor).

Lanifibranor (formerly named as IVA-337) is a novel, potent and well balanced agonist of the pan-peroxisome proliferator-activated receptors (PPAR) with excellent safety profiles and with EC50s of 1.5, 0.87 and 0.21 μM for human PPARα, PPARσ and PPARγ, respectively.